Alemtuzumab 8y outcomes (ECTRIMS 2018)

  UK NHS England MS Treatment algorithm

If you don't know where you are going, all roads lead there; and in this case to alemtuzumab! 

But can alemtuzumab puts its money where it's mouth is? 

In ECTRIMS we saw the publication of one their original clinical trial (CARE-MS II) follow up results after an 8 year period (see poster below).

• 56% (77% of the original participants were included in this analysis) required no further doses of alemtuzumab, i.e. only the first 2 cycles an year apart
• 88% relapse-free
• 78% with disease stability, i.e. stable or improved EDSS scores
• 67% free of MRI activity
• Brain volume loss from baseline though to yr8 was -1.83% (i.e. normal rate as those without MS)
• Side effects were the same as previously described

I'll leave you to come to your own conclusions on these findings, but alemtuzumab is here to stay.